patent.fyi
Applications  /  US 2026/0355205
United States Patent Application Publication

US 2026/0355205 A1

Published
Nov 12, 2026
Filed
Oct 19, 2023
Earliest date on the face
Oct 19, 2022
Classification
A61K 31/522
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Brain imaging without sampling

What ifWhat if magnetic resonance imaging supplied the initial neurological assessment without collecting a specimen?
Claim language“collecting a biological sample”

A magnetic resonance scanner acquires fluid-attenuated and diffusion-weighted images of the brain. A reader records the location and extent of signal abnormalities to characterize the pattern of brain involvement.

1.2Neuronal injury protein measurement

What ifWhat if the sample was tested for a single protein marker of neuronal injury?
Claim language“detecting a gene expression signature”

An antibody-based immunoassay measures neurofilament light chain concentration in cerebrospinal fluid. Serial measurements track changes in a marker of axonal injury.

1.3Antiseizure treatment for complications

What ifWhat if the administered drug controlled seizures associated with the neurological disorder?
Claim language“a therapeutically effective amount of an anti-viral agent”

An antiseizure drug that binds a synaptic vesicle protein reduces recurrent seizure activity. Bedside observation and electroencephalography track clinical and electrical seizures.

1.3Viral DNA guided treatment

What ifWhat if a positive cerebrospinal fluid viral DNA result identified the subject for antiviral treatment?
Claim language“the subject with the gene expression signature”

A diagnostic nucleic acid assay tests cerebrospinal fluid for herpes simplex virus 1 DNA. A positive result supports antiviral treatment when the clinical findings are consistent with herpes simplex encephalitis.

1.3Host response signature

What ifWhat if the gene expression signature used a second host transcript?
Claim language“and a herpes simplex virus 1 (HSV-1)”

A targeted RNA assay measures a transcript affected by the neurological disorder and a second host transcript associated with interferon signaling. The paired measurements characterize the host inflammatory response.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Specimen collection in rural neurology clinics

A rural neurology clinic collects venous blood into an RNA stabilization tube and sends it to a regional molecular laboratory under the tube's validated transport conditions. The laboratory measures the host expression signature and reports the result together with specimen quality metrics. The clinic returns the report to the treating clinician, who reviews it with the neurological findings and virologic results before deciding whether to administer antiviral therapy.

Component substitution

Digital PCR for expression measurement

Reverse transcription droplet digital PCR serves as the gene expression detection step. The assay converts extracted host RNA to complementary DNA, partitions the reaction into droplets, and counts fluorescent positive and negative partitions after amplification. Software estimates transcript concentrations using a Poisson correction and normalizes them to validated reference transcripts. The normalized expression values feed the signature interpretation used in the antiviral treatment review.

Parameter or scale variation

Triplicate measurements with a reserved aliquot

The laboratory divides each stabilized specimen into two aliquots and reserves the second for repeat extraction. It measures each target and reference transcript in three technical replicates from the first extract. The analysis uses the median of three valid measurements and triggers repeat extraction when fewer than two measurements pass assay quality checks. The laboratory releases a signature call for clinical review only after the required measurements pass quality checks.

Combination with existing systems

Results linked to electronic medication ordering

A laboratory information system sends the expression signature, specimen identifier, collection time, and quality status to the electronic health record as structured fields. The record displays the result beside the neurological assessment, separate virologic findings, current medications, and available renal function results. The treating clinician uses the linked medication order screen to select and sign an antiviral prescription when the clinical assessment supports treatment.

Paired expression and virology reporting

For a patient already undergoing a clinically indicated lumbar puncture, the laboratory assigns separate cerebrospinal fluid aliquots to host RNA analysis and a diagnostic viral DNA assay. The laboratory derives the host expression signature from the RNA aliquot and records the viral DNA result as a separate observation. A single report links both observations by collection identifier and includes the quality status for each aliquot. The treating clinician uses the paired report with the neurological assessment when making antiviral treatment decisions.

Automated or data-driven variant

Software scoring with quality control gates

Analysis software ingests transcript measurements with matching reference transcript and assay control results. It checks specimen and control quality, normalizes transcript values, and computes a weighted sum using coefficients fixed during assay validation. It applies validated decision thresholds and returns a detected, undetected, or indeterminate signature result. The treating clinician reviews that result alongside clinical and virologic findings before deciding whether to administer antiviral therapy.

Specific version of a part

Cerebrospinal fluid collection

A clinician collects cerebrospinal fluid by lumbar puncture into sterile polypropylene tubes. A separate aliquot goes into a tube prepared for RNA analysis.

Targeted transcript quantification

Reverse transcription converts sample RNA to complementary DNA. Targeted quantitative polymerase chain reaction measures selected host and viral transcripts, with a reference transcript used to normalize the host measurements.

Intravenous antiviral infusion

An infusion pump administers a nucleoside analogue that inhibits viral DNA polymerase after intracellular activation. The dosing interval reflects renal function, and serum creatinine measurements track renal function during treatment.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 6,958,390 B1
Published
Oct 25, 2005
Filed
Jun 14, 2000
Document BUS 10,046,005 B2
Published
Aug 14, 2018
Filed
Aug 11, 2016
Class
A61K 31/7056
Claim 1
Document A
Document B
1.1collecting a biological sample from the subject,
HSV-negative cerebrospinal fluid (CSF) was obtained from Cenetron Diagnostics by pooling normal patient samples.
A · US 6,958,390 B1 · ¶ 89
1.2detecting a gene expression signature from the biological sample, and
HCV viremia in the blood samples before and after administration of nanoformulations (or controls) were monitored by detection of (+) and/or (−) viral mRNA using RT-PCR.
B · US 10,046,005 B2 · ¶ 93
1.3administering a therapeutically effective amount of an anti-viral agent to the subject with the gene expression signature, wherein the gene expression signature comprises at least one gene affected by the neurological disorder and a herpes simplex virus 1 (HSV-1).
HSV infection is commonly treated using anti-viral agents such as acyclovir, valacyclovir or famciclovir.
A · US 6,958,390 B1 · ¶ 2
The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.
B · US 10,046,005 B2 · abstract

An empty cell means only that no passage was reproduced there.

Statements in these documents
An assay which is faster, less labor intensive and comparable in sensitivity to microtiter plate based assays is desirable.
A · US 6,958,390 B1 · ¶ 3
The methods of the present invention require minimal manipulation and may be used and performed in a closed tube, thereby greatly reducing the risk of contamination and reducing the time and effort needed for the test.
A · US 6,958,390 B1 · ¶ 4
It is therefore imperative to develop a novel, safe and effective formulation for the treatment of HCV infection that can quickly move into the clinical trials in comparison to the standard of care.
B · US 10,046,005 B2 · ¶ 4
The present invention provides a composition effective for treating Hepatitis C Virus (HCV) infection in humans along with minimizing side effects, accelerating response to anti-viral, preventing relapse, and suppressing hepatic fibrosis.
B · US 10,046,005 B2 · ¶ 2
Cite aspatent.fyi, US 2026/0355205 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355205/, SHA-256 0f3a73eae1e4de3311e1e7e4c0c5f1cf06c25d239be01860edb384776f290b73
First published
Permanent addresshttps://patent.fyi/US20260355205/
Content fingerprint (SHA-256)0f3a73eae1e4de3311e1e7e4c0c5f1cf06c25d239be01860edb384776f290b73
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi